Vincent Sghiatti
Family Medicine · Los Angeles, CANPI 1750469318
Payments from drug & device makers
Across 123 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$885
- GSK$387
- Novo Nordisk$346
- Takeda Pharmaceuticals U.S.A., Inc.$343
- Ferring Pharmaceuticals Inc.$158
- Boehringer Ingelheim$102
- plus $576 from 15 others
What the payments were for
- Food & beverage$2,795100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $885 |
| GSK | 10 | $387 |
| Novo Nordisk | 4 | $346 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $343 |
| Ferring Pharmaceuticals Inc. | 11 | $158 |
| Boehringer Ingelheim | 1 | $102 |
| Lilly USA, LLC | 4 | $89 |
| AstraZeneca | 4 | $81 |
| Pfizer | 4 | $72 |
| Amgen | 5 | $72 |
| Roche Diagnostics Corporation | 1 | $40 |
| Eisai Inc. | 2 | $37 |
| ERMI LLC | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Vertiflex, Inc. | 1 | $23 |
| Exeltis, USA Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Linus Health, Inc. | 1 | $22 |
| Aytu Biopharma, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Optos, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,795 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 23 | $11,534 |
| JardianceEmpagliflozin | 14 | $8,027 |
| Levothyroxine Sodium | 26 | $565 |
| Gabapentin | 28 | $446 |
| Rosuvastatin Calcium | 41 | $419 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 29 | $401 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $320 |
| Atorvastatin Calcium | 50 | $280 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 35 | $269 |
| Tamsulosin Hcl | 37 | $248 |
| ClopidogrelClopidogrel Bisulfate | 16 | $176 |
| Amlodipine Besylate | 28 | $172 |
| Lorazepam | 22 | $169 |
| Famotidine | 14 | $132 |
| Lisinopril | 29 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $72 | $11,53423 claims |
| Boehringer IngelheimJardiance | $102 | $8,02714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Los Angeles
- Albert NassirLos Angeles$5.7M
- Nader SobhLos Angeles$4.1M
- Alexander RivkinLos Angeles$2.8M
- Pamela KushnerLos Angeles$1.2M
- Scott HowellLos Angeles$793K
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.